TY - JOUR
AU - Herman, Bianka Edina
AU - Gardi, János
AU - Julesz, János
AU - Tömböly, Csaba
AU - Szánti-Pintér, Eszter
AU - Fehér, Klaudia
AU - Skodáné Földes, Rita
AU - Szécsi, Mihály
TI - Steroidal ferrocenes as potential enzyme inhibitors of the estrogen biosynthesis
JF - BIOLOGIA FUTURA
J2 - BIOL FUTURA
VL - 71
PY - 2020
IS - 3
SP - 249
EP - 264
PG - 16
SN - 2676-8615
DO - 10.1007/s42977-020-00023-7
UR - https://m2.mtmt.hu/api/publication/31365295
ID - 31365295
N1 - cited By 4
LA - English
DB - MTMT
ER -
TY - JOUR
AU - Szabó, Renáta
AU - Ménesi, Rudolf
AU - Molnár, Andor
AU - Szalai, Zita
AU - Daruka, Lejla
AU - Tóth, Gábor
AU - Gardi, János
AU - Gálfi, Márta
AU - Börzsei, Denise
AU - Kupai, Krisztina
AU - Juhász, Anna
AU - Radács, Marianna
AU - László, Ferenc
AU - Varga, Csaba
AU - Pósa, Anikó
TI - New Metabolic Influencer on Oxytocin Release: The Ghrelin
JF - MOLECULES
J2 - MOLECULES
VL - 24
PY - 2019
IS - 4
PG - 8
SN - 1420-3049
DO - 10.3390/molecules24040735
UR - https://m2.mtmt.hu/api/publication/30446615
ID - 30446615
N1 - The study was supported by GINOP-2.3.2-15-2016-00062 and the Ministry of Human Capacities, Hungary grant 20391-3/2018/FEKUSTRAT is acknowledged. Furthermore, this work has been supported by the European Union, cofinanced by the European Social Fund EFOP-3.6.2-16-2017-00009.
LA - English
DB - MTMT
ER -
TY - JOUR
AU - Schuster, Sabine
AU - Biri-Kovács, Beáta
AU - Szeder, Bálint
AU - Buday, László
AU - Gardi, János
AU - Szabó, Zsuzsanna
AU - Halmos, Gábor
AU - Mező, Gábor
TI - Enhanced In Vitro Antitumor Activity of GnRH-III-Daunorubicin Bioconjugates Influenced by Sequence Modification
JF - PHARMACEUTICS
J2 - PHARMACEUTICS
VL - 10
PY - 2018
IS - 4
PG - 19
SN - 1999-4923
DO - 10.3390/pharmaceutics10040223
UR - https://m2.mtmt.hu/api/publication/30445256
ID - 30445256
N1 - Funding Agency and Grant Number: European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie Grant [642004]; National Research, Development and Innovation Office [NKFIH K119552, NVKP_16-1-2016-0036]; Higher Education Institutional Excellence Programme of the Ministry of Human Capacities in Hungary, within University of Debrecen [20428-3/2018/FEKUTSTRAT]; European Union; European Regional Development Fund; MedInProt; [GINOP-2.3.2-15-2016-00043]
Funding text: This work was supported by the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie Grant No. 642004; and by the National Research, Development and Innovation Office under grant NKFIH K119552 and NVKP_16-1-2016-0036. The work is also supported by the GINOP-2.3.2-15-2016-00043 (G.H.) project and by the Higher Education Institutional Excellence Programme of the Ministry of Human Capacities in Hungary, within the framework of the Biotechnology Thematic Programme 20428-3/2018/FEKUTSTRAT of the University of Debrecen (G.H.). The project is co-financed by the European Union and the European Regional Development Fund. Financial resources for the western blot detection system were provided by MedInProt.
AB - Receptors for gonadotropin releasing hormone (GnRH) are highly expressed in various human cancers including breast, ovarian, endometrial, prostate and colorectal cancer. Ligands like human GnRH-I or the sea lamprey analogue GnRH-III represent a promising approach for the development of efficient drug delivery systems for targeted tumor therapy. Here, we report on the synthesis and cytostatic effect of 14 oxime bond-linked daunorubicin GnRH-III conjugates containing a variety of unnatural amino acids within the peptide sequence. All compounds demonstrated a reduced cell viability in vitro on estrogen receptor α (ERα) positive and ERα negative cancer cells. The best candidate revealed an increased cancer cell growth inhibitory effect compared to our lead-compound GnRH-III-[⁴Lys(Bu),⁸Lys(Dau=Aoa)]. Flow cytometry and fluorescence microscopy studies showed that the cellular uptake of the novel conjugate is substantially improved leading to an accelerated delivery of the drug to its site of action. However, the release of the active drug-metabolite by lysosomal enzymes was not negatively affected by amino acid substitution, while the compound provided a high stability in human blood plasma. Receptor binding studies were carried out to ensure a high binding affinity of the new compound for the GnRH-receptor. It was demonstrated that GnRH-III-[²ΔHis,³d-Tic,⁴Lys(Bu),⁸Lys(Dau=Aoa)] is a highly potent and promising anticancer drug delivery system for targeted tumor therapy.
LA - English
DB - MTMT
ER -
TY - JOUR
AU - Demeter-Haludka, Vivien
AU - Juhász, László
AU - Kovács, Mária
AU - Gardi, János
AU - Végh, Ágnes
TI - Is there a role of iNOS activation in the delayed antiarrhythmic effect of sodium nitrite?
JF - CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY
J2 - CAN J PHYSIOL PHARM
VL - 95
PY - 2017
IS - 4
SP - 447
EP - 454
PG - 8
SN - 0008-4212
DO - 10.1139/cjpp-2016-0357
UR - https://m2.mtmt.hu/api/publication/3184963
ID - 3184963
N1 - Department of Pharmacology and Pharmacotherapy, University of Szeged, Albert-Szent Györgyi Medical Centre, Szeged, H-6720, Hungary
First Department of Internal Medicine, University of Szeged, Albert-Szent Györgyi Medical Centre, Szeged, H-6720, Hungary
Cited By :2
Export Date: 31 May 2021
CODEN: CJPPA
Correspondence Address: Végh, Á.; Department of Pharmacology and Pharmacotherapy, Hungary; email: vegh.agnes@med.u-szeged.hu
Chemicals/CAS: inducible nitric oxide synthase, 501433-35-8; nitrate, 14797-55-8; nitrite, 14797-65-0; sodium chloride, 7647-14-5; sodium nitrite, 7632-00-0; aminoethylisothiouronium, 151-16-6, 55818-78-5, 56-10-0; nitric oxide, 10102-43-9; Anti-Arrhythmia Agents; beta-Aminoethyl Isothiourea; Nitric Oxide; Nitric Oxide Synthase Type II; Sodium Nitrite
Department of Pharmacology and Pharmacotherapy, University of Szeged, Albert-Szent Györgyi Medical Centre, Szeged, H-6720, Hungary
First Department of Internal Medicine, University of Szeged, Albert-Szent Györgyi Medical Centre, Szeged, H-6720, Hungary
Cited By :2
Export Date: 21 June 2021
CODEN: CJPPA
Correspondence Address: Végh, Á.; Department of Pharmacology and Pharmacotherapy, Hungary; email: vegh.agnes@med.u-szeged.hu
Chemicals/CAS: inducible nitric oxide synthase, 501433-35-8; nitrate, 14797-55-8; nitrite, 14797-65-0; sodium chloride, 7647-14-5; sodium nitrite, 7632-00-0; aminoethylisothiouronium, 151-16-6, 55818-78-5, 56-10-0; nitric oxide, 10102-43-9; Anti-Arrhythmia Agents; beta-Aminoethyl Isothiourea; Nitric Oxide; Nitric Oxide Synthase Type II; Sodium Nitrite
AB - This study aimed to examine whether inducible nitric oxide synthase (iNOS) plays a role in the delayed antiarrhythmic effect of sodium nitrite. Twenty-one dogs were infused intravenously with sodium nitrite (0.2 micromol/kg/min) for 20 min, either in the absence (n=12) or in the presence of the iNOS inhibitor S-(2-aminoethyl)-isothiourea (AEST; total dose: 2.0 mg/kg; i.v., n=9). Control dogs (n=12) were given saline. Twenty-four hours later, all the dogs were subjected to a 25 min period occlusion of the left anterior descending (LAD) coronary artery, followed by rapid reperfusion. Dogs treated with AEST and nitrite were received again AEST prior to the occlusion. Compared to the controls, sodium nitrite markedly reduced the number of ectopic beats, the number and incidence of ventricular tachycardia and the incidence of ventricular fibrillation during occlusion and increased survival (0% vs. 50%) from the combined ischaemia and reperfusion insult. Although AEST completely inhibited iNOS activity, the nitrite induced increased NO bioavailability during occlusion was not substantially modified. Furthermore, AEST attenuated but did not completely abolish the antiarrhythmic effect of nitrite. The marked delayed antiarrhythmic effect of sodium nitrite is not entirely due to the activation of iNOS; other mechanisms may certainly play a role.
LA - English
DB - MTMT
ER -
TY - JOUR
AU - Gálfi, Márta
AU - Radács, Marianna
AU - Molnár, Zsolt
AU - Budai, I
AU - Tóth, Gábor
AU - Pósa, Anikó
AU - Kupai, Krisztina
AU - Szalai, Zita
AU - Szabó, Renáta
AU - Molnár, Andor
AU - Gardi, János
AU - Laszlo, FA
AU - Varga, Csaba
TI - Ghrelin-Induced Enhancement of Vasopressin and Oxytocin Secretion in Rat Neurohypophyseal Cell Cultures
JF - JOURNAL OF MOLECULAR NEUROSCIENCE
J2 - J MOL NEUROSCI
VL - 60
PY - 2016
IS - 4
SP - 525
EP - 530
PG - 6
SN - 0895-8696
DO - 10.1007/s12031-016-0850-4
UR - https://m2.mtmt.hu/api/publication/3130700
ID - 3130700
AB - The effects of ghrelin on vasopressin and oxytocin secretion
were studied in 13-14-day cell cultures of isolated rat
neurohypophyseal tissue. The vasopressin and oxytocin
contents of the supernatant were determined by
radioimmunoassay after a 1- or 2-h incubation. Significantly
increased levels of vasopressin and oxytocin production were
detected in the cell culture media following ghrelin
administration, depending on the ghrelin doses. The oxytocin
level proved to be more elevated than that of vasopressin.
The increase of vasopressin and oxytocin secretion could be
totally blocked by previous administration of the ghrelin
receptor antagonist ([D-Lys3]-growth hormone-releasing
peptide-6). Application of the ghrelin receptor antagonist
after ghrelin administration proved ineffective. The results
indicate that vasopressin and oxytocin release is influenced
directly by the ghrelin system, and the effects of ghrelin on
vasopressin and oxytocin secretion from the neurohypophyseal
tissue in rats can occur at the level of the posterior
pituitary. Our observations lend support to the view that
neurohypophysis contains ghrelin receptors.
LA - English
DB - MTMT
ER -
TY - CONF
AU - Herman, Bianka Edina
AU - Szabó, Johanna
AU - Bacsa, Ildikó
AU - Wölfling, János
AU - Schneider, Gyula
AU - Mernyák, Erzsébet
AU - Szécsi, Mihály
AU - Gardi, János
AU - Valkusz, Zsuzsanna
TI - A 17β-HSD1 enzimaktivitás in vitro vizsgálata 13α-ösztron származékokkal. A Magyar Endokrinológiai és Anyagcsere Társaság XXVI. Jubileumi Kongresszusa
TS - A Magyar Endokrinológiai és Anyagcsere Társaság XXVI. Jubileumi Kongresszusa
T2 - A Magyar Endokrinológiai és Anyagcsere Társaság XXVI. Jubileumi Kongresszusa
PB - Medicina Könyvkiadó
C1 - Budapest
PY - 2016
SP - 159
EP - 159
PG - 1
UR - https://m2.mtmt.hu/api/publication/3081947
ID - 3081947
LA - Hungarian
DB - MTMT
ER -
TY - JOUR
AU - Valkusz, Zsuzsanna
AU - Sepp, Krisztián
AU - Gardi, János
AU - Patócs, Attila Balázs
TI - Screening and follow up of an extended Hungarian family with familial medullary thyroid cancer
JF - ENDOCRINE ABSTRACTS
J2 - ENDOCR ABSTR
VL - 41
PY - 2016
SN - 1470-3947
DO - 10.1530/endoabs.41.EP1109
UR - https://m2.mtmt.hu/api/publication/3072269
ID - 3072269
LA - English
DB - MTMT
ER -
TY - GEN
AU - Valkusz, Zsuzsanna
AU - Sepp, Krisztián
AU - Gardi, János
AU - Patócs, Attila Balázs
TI - Screening and follow up of an extended Hungarian family with familial medullary thyroid cancer
PY - 2016
UR - https://m2.mtmt.hu/api/publication/3072268
ID - 3072268
LA - English
DB - MTMT
ER -
TY - CHAP
AU - Szabó, N
AU - Ajdukovic, JJ
AU - Sakac, MN
AU - Durendic, EA
AU - Jovanovic-Santa, SS
AU - Penov, Gasi KM
AU - Gardi, János
AU - Pajor, L
AU - Julesz, János
AU - Szécsi, Mihály
ED - Szélpál, Szilárd
TI - A 17α-hidroxiláz-C17,20-liáz (P45017α) enzim aktivitásának gátlása N-oxi 17-pikolinilidén szteroid származékokkal
T2 - Innováció a Természettudományban – Doktorandusz konferencia
PB - Magyar Kémikusok Egyesülete Biokémiai Szakosztály
CY - Szeged
SN - 9789639970632
PY - 2015
SP - 41
EP - 41
PG - 1
UR - https://m2.mtmt.hu/api/publication/3023632
ID - 3023632
LA - Hungarian
DB - MTMT
ER -
TY - JOUR
AU - Kiscsatári, Laura
AU - Varga, Zoltán
AU - Molnár-Gáspár, Renáta
AU - Görbe, Anikó
AU - Ferdinandy, Péter
AU - Gardi, János
AU - Kahán, Zsuzsanna
TI - A növekedésihormon-felszabadító hormon (GHRH) receptorok potenciális szerepe radioaktív szívkárosodás esetén
JF - MAGYAR ONKOLÓGIA
J2 - MAGYAR ONKOLÓGIA
VL - 59
PY - 2015
IS - 2
SP - 169
EP - 170
PG - 2
SN - 0025-0244
UR - https://m2.mtmt.hu/api/publication/2902081
ID - 2902081
N1 - http://huon.hu/2015/59/2/0162/0162a.pdf
LA - Hungarian
DB - MTMT
ER -